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The mammalian intestinal tract is heavily colonized with a dense, complex, and
diversified microbial populations. In healthy individuals, an array of epithelial antimicrobial
agents is secreted in the gut to aid intestinal homeostasis. Enterochromaffin cells
(EC) in the intestinal epithelium are a major source of chromogranin A (CgA), which
is a pro-hormone and can be cleaved into many bioactive peptides that include
catestatin (CST). This study was carried out to evaluate the possible impact of CST
on gut microbiota in vivo using a mouse model. The CST (Human CgA352−372) or
normal saline was intrarectally administered in C57BL/6 male mice for 6 days and
then sacrificed. Feces and colonic mucosa tissue samples were collected, DNA was
extracted, the V4 region of bacterial 16S rRNA gene was amplified and subjected to
MiSeq Illumina sequencing. The α-diversity was calculated using Chao 1 and β-diversity
was determined using QIIME. Differences at the genus level were determined using partial
least square discriminant analysis (PLS-DA). Phylogenetic investigation of communities
by reconstruction of unobserved states (PICRUSt) was used to predict functional
capacity of bacterial community. CST treatment did not modify bacterial richness
in fecal and colonic mucosa-associated microbiota; however, treatment significantly
modified bacterial community composition between the groups. Also, CST-treated mice
had a significantly lower relative abundance of Firmicutes and higher abundance of
Bacteroidetes, observed only in fecal samples. However, at lower phylogenetic levels,
PLS-DA analysis revealed that some bacterial taxa were significantly associated with the
CST-treated mice in both fecal and colonic mucosa samples. In addition, differences
in predicted microbial functional pathways in both fecal and colonic mucosa samples
were detected. The results support the hypothesis that CST treatment modulates gut
microbiota composition under non-pathophysiological conditions, however, the result of
this study needs to be further validated in a larger experiment. The data may open new
avenues for the development of a potential new line of antimicrobial peptides and their
use as therapeutic agents to treat several inflammatory conditions of the gastrointestinal
tract, such as inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), or
other health conditions.
Keywords: gutmicrobiota, intestinal homeostasis, chromogranin A (CgA), catestatin (CST), antimicrobial peptides,
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INTRODUCTION
Over the last 15 years, bacterial multi-drug resistance (MDR) has
emerged as a result of several socio-economical reasons, such as
the use of surface antibacterial agents that are now available in
many household products (Davies and Davies, 2010), antibiotic
over-prescription, or failing to complete a course of antibiotics
(Davies and Davies, 2010). Although due to MDR new line of
antibiotics are required, development of new antibiotics has been
reduced by pharmaceutical companies because of the cost and
complexity of clinical trials (Mullard, 2014). Currently, there are
relatively few new antimicrobials in development.
The gastrointestinal (GI) tract is heavily colonized with an
average of 1014 microbes that represent thousands of species,
which is 10 times more than the total number of cells in the
human body (Yu and Huang, 2013). More than 90% of members
of this bacterial community belong to two major phyla: gram-
negative Bacteriodetes and gram-positive Firmicutes (Peterson
et al., 2008; Kaser et al., 2010), with the remaining belong to
low-abundance phyla such as Proteobacteria and Actinobacteria.
Viruses, protists, and fungi are also other members of gut
microbiome (Peterson et al., 2008; Kaser et al., 2010). In
healthy individuals and during certain age categories, microbial
diversity in the intestine is stable over time and demonstrates
a symbiotic relationship with the host (Yu and Huang, 2013),
but a shift in microbial composition, referred to as dysbiosis,
has been described in several pathologies (Kallus and Brandt,
2012; Collins, 2014; Carding et al., 2015). Gut microbiota helps to
digest food items. Various metabolites produced by the resident
microbiota play a significant role in host physiology, metabolism
and immune function. For example, gut microbiota can activate
toll-like receptors (TLRs) in the gut epithelium, which in turn
can affect the expression of antimicrobial peptides, such as
angiogenins (Vaishnava et al., 2008; Raybould, 2012). In addition
to the innate immune system, gut microbiota can also control
the host’s adaptive immune system through T cell receptor αβ-
positive intraepithelial lymphocytes, regulatory T cells and T
helper 17 cells (Kaser et al., 2010). Overall, gut homeostasis is
largely dependent on the proper balance and composition of gut
microbiome (Stecher and Hardt, 2008).
At the mucosal level the epithelium plays a major role in
limiting the passage/penetration of bacteria to the sub-mucosa
from the gut lumen. Antimicrobial peptides (AMPs) secreted
by epithelial cells have a broad spectrum effect against bacteria
and are a part of an ancient defense mechanism that is present
in virtually all mammals (Ostaff et al., 2013). In the GI tract,
specialized intestinal epithelial cells or circulating inflammatory
cells are a major source of these AMPs (Ostaff et al., 2013).
Within the epithelium, Paneth cells are the main producer of
AMPs but new data indicate that enterochromaffin (EC) cells can
hypothetically also produce certain types of AMPs (Khan and
Ghia, 2010).
EC cells are the major source of chromogranin A (CgA;
Norlén et al., 2001), a family of highly acidic proteins. The CgA
gene is localized at 14q32 in the human genome, consisting
of eight exons and seven introns, and its 2-Kb transcript
is translated into the 457-residue CgA protein. The overall
homology for CgA in different vertebrates is ∼40%, but the
most highly conserved regions occur at the N- and C-termini,
which show up to 88% sequence homology. Cell- and tissue-
specific CgA processing has been described in the rat, mouse,
and human GI tract (Curry et al., 1991; Portela-Gomes and
Stridsberg, 2001, 2002). The CgA primary structure from its
cDNA sequence shows the presence of numerous pairs of basic
amino acids. These are potential sites for cleavage by prohormone
convertases (PC) 1/3 or 2, and carboxypeptidase E/H (Seidah and
Chrétien, 1999), which is consistent with evidence that CgA may
serve as a prohormone for shorter bioactive fragments (Eiden,
1987); this is also suggested by the high sequence conservation
of CgA-derived peptides. But in the gut, peptides can be
highly sensitive to enzymes present in the luminal environment.
Proteolytic fragments of CgA-derived peptides exert a broad
spectrum of regulatory activities on the cardiovascular, endocrine
and immune systems. Among its highly conserved C-terminal
regions, CgA gives rise to a peptide of biological importance: the
antihypertensive peptide catestatin (human CST; CgA352−372)
(Mahata et al., 1997, 2010; Mahapatra et al., 2005), which has
restricted antimicrobial activity against Staphylococcus aureus
in vitro (Briolat et al., 2005). Similar to other AMPs, CST can
interact with anionic components of fungi and bacteria. As a
result, the microbial membrane is permeabilized, leading to cell
lysis (Boman et al., 1993). In vitro studies have demonstrated
that CST is effective against gram-positive bacteria, such as
S. aureus and group A Streptococcus; gram-negative bacteria,
such as Escherichia coli, Pseudomonas aeruginosa; yeasts, such
as Candida albicans; and filamentous fungi, such as Aspergillus
niger, Aspergillus fumigatus, and Trichophyton rubrum (Boman
et al., 1993; Dorschner et al., 2001). However, to date, there has
been no indication that the in vitro data can be reproduced using
an in vivo model and whether or not the effect of CST would
be similar in different gut compartment as the colonic mucosa-
associated populations differ from the populations present in the
feces (Zoetendal et al., 2002).
Despite the effects of CST on S. aureus, E. coli, and
P. aeruginosa populations in vitro, the effects of in vivo CST
treatment onmicrobiota across the GI tract is unknown. Our aim
was to assess the compositional shifts and functional alterations
in the fecal and colonic mucosa-associated microbiota in mice
that were exposed to CST for 6 days.
MATERIALS AND METHODS
Animals
Male C57BL/6 mice (7–9 weeks old) were purchased from
Charles River (Canada) and maintained in the animal care
facility at the University of Manitoba. The experimental protocol
was approved by the University of Manitoba Animal Ethics
Committee (15-010) and the research was conducted according
to the Canadian Guidelines for Animal Research (Gauthier, 2002;
Demers et al., 2006). Two groups of four and eight mice were
studied, one receiving the vehicle solution and one receiving
intra-rectal (i.r.) infusion of CST for 6 days. By using mice
from the same sex, source, age, and keeping them in co-housed
conditions while receiving the same food, the environmental
effects on gut microbiota were minimized.
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Peptide
The CST (Human CgA352−372: SSMKLSFRARAYGFRGPGPQL)
(Mahata et al., 2010) was used (Biopeptide Co., Inc., San Diego,
CA, USA), and the peptide was injected (i.r.) at 1.5 mg/per kg
body weight per day for 6 days. Saline (0.9%) was injected in the
control group. Mice were anesthetized using isoflurane (Abbott,
Toronto, ON, Canada). PE-90 tubing (10 cm long; ClayAdam,
Parisppany, NJ, USA), which was attached to a tuberculin syringe
(BD, Mississauga, ON, Canada), was inserted 3.5 cm into the
colon. The dose was determined according to our previous
published study (Rabbi et al., 2014).
Assessment of Physiological Condition
Weight loss, stool consistency, and bleeding were assessed daily
to determine any possible physical changes in the mice as a result
of CST treatment (Cooper et al., 1993). Scores were defined as
follows: weight: 0, no loss; 1, 5–10%; 2, 10–15%; 3, 15–20%; and
4, 20%weight loss; stool: 0, normal; 2, loose stool; and 4, diarrhea;
and bleeding: 0, no blood; 2, presence of blood; and 4, gross
blood. Blood was assessed using the Hemoccult II test (Beckman
Coulter, Oakville, ON, Canada).
Fecal and Tissue Sample Collection
Samples were collected 6 days post-treatment induction, after
euthanasia under isoflurane (Abbot) anesthesia. Themacroscopic
score was determined on the sacrifice day based on stool
consistency, rectal prolapse, and rectal and colonic bleeding. On
the day of sacrifice, the colon was opened and approximately a
250mg fecal sample was collected near the rectal opening. In
addition, a portion of the colon tissue was collected within 5 cm
from rectal opening. Approximately 50mg of mucosa scrapings
were collected from these colon tissue. All samples were collected
in individual collector tubes from each animal and snap frozen in
liquid nitrogen and preserved at−80◦C until use.
DNA Extraction and Quality Check
Samples were homogenized at room temperature, and genomic
DNA was extracted from mucosa scarpings using a ZR Tissue
and Insect DNA extraction Kit (Zymo Research Corp., Orange,
CA, USA). Fecal DNA extraction was performed using a ZR fecal
DNA extraction kit (Zymo Research Corp., Orange, CA). Both
DNA extraction kits had a bead-beating step to mechanically
lyse microbial cells. DNA was quantified using a Nanodrop 2000
spectrophotometer (Thermo Scientific, Wilmington, DE, USA).
DNA samples were normalized to achieve a concentration of 20
ng/µl, and quality-checked by PCR amplification of 16S rRNA
gene using primers 27F (5′-GAAGAGTTTGATCATGGCTCAG-
3′) and 342R (5′-CTGCTGCCTCCCGTAG-3′) (Sepehri et al.,
2007; Khafipour et al., 2009). Amplicons were verified by agarose
gel electrophoresis.
Library Construction and Illumina
Sequencing
Library construction and Illumina sequencing were performed
as described by Derakhshani et al. (2016) Briefly, the V4 region
of the 16S rRNA gene was targeted for PCR amplification
using modified F515/R806 primers (Caporaso et al., 2012). A
reverse PCR primer was indexed with 12-base Golay barcodes
to allow for sample multiplexing. The PCR reaction for each
sample was performed in duplicate and contained 1.0 µl of
pre-normalized DNA, 1.0 µl each of forward and reverse primers
(10 µM), 12 µl HPLC grade water (Fisher Scientific, Ottawa,
ON, Canada) and 10 µl 5 Prime Hot MasterMix (5 Prime,
Inc., Gaithersburg, MD, USA). Reactions consisted of an initial
denaturing step at 94◦C for 3 min followed by 35 amplification
cycles at 94◦C for 45 s, 50◦C for 60 s and 72◦C for 90 s; this
was followed by an extension step at 72◦C for 10 min in an
Eppendorf Mastercycler (Eppendorf, Hamburg, Germany).
PCR products were then purified using a ZR-96 DNA Clean-up
Kit (ZYMO Research, Irvine, CA, USA) to remove primers,
dNTPs and reaction components. The V4 library was then
generated by pooling 200 ng of each sample, and quantified
using Picogreen dsDNA (Invitrogen, Carlsbad, CA, USA).
This was followed by multiple dilution steps using pre-chilled
hybridization buffer (HT1) (Illumina, San Diego, CA, USA) to
bring the pooled amplicons to a final concentration of 5 pM, and
the concentration was measured through optical density using
a Qubit 2.0 Fluorometer (Life technologies, Burlington, ON,
Canada). Finally, 15% of the PhiX control library was spiked into
the amplicon pool to improve the unbalanced and biased base
composition, a known characteristic of low diversity 16S rRNA
libraries. Customized sequencing primers for read1 (5′-TAT
GGTAATTGTGTGCCAGCMGCCGCGGTAA-3′), read2 (5′-
AGTCAGTCAGCCGGACTACHVGGGTWTCTAAT-3′), and
index read (5′-ATTAGAWACCCBDGTAGTCCGGCTGACT
GACT-3′) were synthesized and purified using polyacrylamide
gel electrophoresis (Integrated DNA Technologies, Coralville,
IA, USA) and added to the MiSeq Reagent Kit V2 (300-cycle)
(Illumina, CA, USA). The 150 paired-end sequencing reaction
was performed on a MiSeq platform (Illumina, CA, USA) at the
Gut Microbiome and Large Animal Biosecurity Laboratories,
Department of Animal Science, University of Manitoba, Canada.
The sequencing data are uploaded into the Sequence Read
Archive (SRA) of NCBI (http://www.ncbi.nlm.nih.gov/sra) and
are accessible through accession number SRR2830596.
Bioinformatics Analyses
Bioinformatics analyses were performed as described previously
(Derakhshani et al., 2016). Briefly, the PANDAseq assembler
(Masella et al., 2012) was used to merge overlapping paired-end
Illumina fastq files. All the sequences with mismatches or
ambiguous calls in the overlapping region were discarded.
The output fastq file was then analyzed using downstream
computational pipelines in the open source software package
QIIME (Caporaso et al., 2010a). Chimeric reads were filtered
using UCHIME (Edgar et al., 2011) and sequences were
assigned to operational taxonomic units (OTU) using the
QIIME implementation of UCLUST (Edgar, 2010) at the
97% pairwise identity threshold. Taxonomies were assigned
to the representative sequence of each OTU using an
RDP classifier (Wang et al., 2007) and aligned with the
Greengenes (v. 13.5) core reference database (DeSantis et al.,
2006) using PyNAST algorithms (Caporaso et al., 2010b).
The phylogenetic tree was built with FastTree 2.1.3 (Price
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et al., 2010) for additional comparisons between microbial
communities.
Alpha (α)- and Beta (β)-Diversity Analyses
Within-community diversity (α-diversity) was calculated using
QIIME and differences between control and CST groups were
determined using SAS (SAS 9.3). An α rarefaction curve
was generated using a Chao 1 estimator of species richness
(Chao, 1984) with 10 sampling repetitions at each sampling
depth. An even depth of ∼15,700 sequences per sample was
used for calculation of richness and diversity indices. To
compare microbial composition between samples, β-diversity
was measured by calculating the weighted and unweighted
UniFrac distances (Lozupone and Knight, 2005) using QIIME
default scripts. Principal coordinate analysis (PCoA) was applied
on the resulting distance matrices to generate two-dimensional
plots using PRIMER v6 software (Warwick and Clarke, 2006).
Permutational multivariate analysis of variance of Bray-Curtis
distance (PERMANOVA; Anderson, 2005) was used to calculate
P-values and test for significant differences in β-diversity among
treatment groups.
Partial Least Square Discriminant Analysis
Partial least square discriminant analysis (PLS-DA; SIMCA P+
13.0, Umetrics, Umea, Sweden) was performed on the genus data
to identify the effects of treatments (Li et al., 2012; Derakhshani
et al., 2016). The PLS-DA is a particular case of partial least square
regression analysis in which Y is a set of variables describing
categories of variables on X. In this case, X variables were
the bacterial genera and the Y variables were observations of
different treatment groups compared together. To avoid over-
parameterization of the model, the variable influence on the
projection (VIP) value was estimated for each genus, and genera
with VIP < 0.50 were removed from the final model (Pérez-
Enciso and Tenenhaus, 2003; Verhulst et al., 2011). R2 estimate
then was used to evaluate the goodness of fit and Q2 estimate
was used to evaluate the predictive value of the model. The PLS-
regression coefficients were used to identify genera that were
most characteristic of each treatment group and the results were
visualized by PLS-DA loading scatter plots.
Metagenomic Functional Prediction
The open source software PICRUSt (Phylogenetic Investigation
of Communities by Reconstruction of unobserved States; v. 1.0.0-
dev) was used to predict the functional capacity of microbiome
using 16S rRNA gene sequencing data and Greengenes (v.
13.5) reference database (Langille et al., 2013). To make
our open-reference picked OTUs compatible with PICRUSt,
all de-novo OTUs were removed and only those that had
matching Greengenes identifications were retained. The new
OTU table was then used to generate metagenomic data after
normalizing the data by copy numbers, and to derive relative
Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway
abundance (Langille et al., 2013). The KEGG data were analyzed
using STAMP (STatistical Analysis of Metage- nomic Profiles;
Parks and Beiko, 2010).
Other Statistical Analysis
The SAS UNIVARIATE procedure (SAS 9.3) was used to test
the normality of residuals for α biodiversity data. Non-normally
distributed data were log transformed and then used to assess
the effect of sampling using the SAS MIXED procedure. The
SAS MIXED procedure was used, as described above, to test
for significant changes in the proportions of different phyla
among the groups of interest. Differences between groups were
considered significant at P < 0.05 while trends were observed at
P < 0.1.
RESULTS
Descriptive Analysis
Over the 6 days of treatment, daily i.r. infusion of the peptide did
not show any effect on the weight, stool consistency, and presence
of blood in the feces. The data are consistent with our previous
findings (Rabbi et al., 2014; data not shown).
Sample Assessment by Illumina
Sequencing
After sacrifice, we collected fecal and colon samples from a
total of 12 mice. Among these, the control group received
normal saline i.r and the others received CST i.r. (1.5mg per kg
body weight for 6 days). During the DNA extraction process,
one colonic mucosa sample from the saline-treated group was
discarded because of poor quality or purity, resulting in a total of
12 useable fecal samples and 11 useable colonic mucosa samples
for Illumina sequencing. For fecal samples, a total of 328,085
sequences were generated. After quality-filtering steps, an average
of 27,340 high quality sequences per sample was obtained. For
colonic mucosa samples, a total of 207,123 sequences were
generated. After quality-filtering steps, an average of 18,829 high-
quality sequences per sample was obtained.
CST Exposure Did Not Significantly
Influence α-Diversity in Fecal and Colonic
Mucosa Samples in Mice
Bacterial richness and diversity from both fecal and colonic
mucosa samples between control and CST-treated groups were
calculated. However, no significant differences were observed in
both fecal and colon samples (data not shown).
CST Treatment Significantly Influenced
β-Diversity in Fecal Samples But Not in
Colonic Mucosa Samples in Mice
Bacterial communities from fecal samples of CST-treated mice
clustered separately (P < 0.05) from controls suggesting that
the treatment modified the fecal bacterial profile (Figure 1).
However, there was no significant change in the bacterial
community composition in colonic samples in CST-treated mice
compared to controls (Figure 2).
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FIGURE 1 | PCoA based on the unweighted and weighted UniFrac distance metric. Each colored point represents a fecal sample obtained from one mice and
it is colored according to different treatment (CST or Control). P-values were calculated using PERMANOVA. Samples clustered according to treatment status of the
mice (P < 0.05).
FIGURE 2 | PCoA based on the unweighted and weighted UniFrac distance metric. Each colored point represents a colonic mucosa-associated sample
obtained from one mice and it is colored according to different treatment (CST or Control). P-values were calculated using PERMANOVA. Samples did not cluster
according to treatment status of the mice (P > 0.05).
CST Treatment Influenced Fecal But Not
Colonic Mucosa- Associated Bacterial
Community Composition at the Phylum
Level in Mice
In the fecal samples, a total of 10 phyla were identified, of
which four phyla were considered to be abundant within the
community (≥1%); these included Firmicutes, Bacteroidetes,
Proteobacteria, and Deferribacteres. The other six phyla were
in low abundance within the community (<1%) and included
Actinobacteria, Cyanobacteria, Fibrobacteres, TM7, Tenericutes,
and Verrucomicrobia (Table 1). Among the four abundant phyla,
CST treatment increased the relative abundance of Bacteroidetes
(P < 0.05) and decreased the Firmicutes proportion (P < 0.001)
in the feces (Figure 3).
In the colonic mucosa samples, a total of 19 phyla were
identified, of which four phyla were considered to be abundant
within the community; these included Firmicutes, Bacteroidetes,
Proteobacteria, and Deferribacteres. The other 15 phyla
were in low abundance within the community, and included
Acidobacteria, Actinobacteria, Armatimonadetes, Chlamydiae,
Chlorobi, Cyanobacteria, Fibrobacteres, Lentisphaerae, OD1,
OP3, Planctomycetes, Spirochaetes, TM7, Tenericutes,
and Verrucomicrobia (Table 2). CST treatment had no
significant impact on the relative abundance of bacterial phyla
(Figure 4).
CST Treatment Influenced Fecal Bacterial
Community Composition at the Lower
Taxonomical Levels in Mice
A total of 86 bacterial taxa were identified. While majority of
taxa were classified at the genus or species levels, some were
only classified at the phylum (P), class (C), order (O), or family
(F) levels. Of the 86 taxa, 54 taxa were considered abundant
within the community, while 32 were in low abundance. Results
of the relative abundance of various genera with percentages of
sequences ≥0.01% of community were analyzed using PLS-DA
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TABLE 1 | Relative abundances of bacterial phyla in fecal samples.
Phylum Groups Mean percentage of
sequence in total
bacterial community
SEM
Unclassified Control 0.496921 0.092571
CST 0.414249 0.04264
Actinobacteria Control 0.511464 0.202226
CST 0.187706 0.09371
Bacteroidetes Control 59.59139 4.253899
CST 73.99889 2.680188
Cyanobacteria Control 0.017379 0.006038
CST 0.152001 0.041196
Deferribacteres Control 1.709693 1.021632
CST 1.143747 0.782717
Fibrobacteres Control 0.001941 0.00115
CST 0.000541 0.000541
Firmicutes Control 33.80289 3.56062
CST 20.55645 1.827242
Proteobacteria Control 2.218421 0.409325
CST 2.872719 0.488761
TM7 Control 0.003883 0.002301
CST 0.003098 0.001035
Tenericutes Control 0.314479 0.089961
CST 0.404554 0.187125
Verrucomicrobia Control 1.331539 0.730169
CST 0.266048 0.129101
FIGURE 3 | Effect of CST treatment on the abundant phyla (≥1%)
present in the fecal samples. After quality filtering steps, 10 bacterial phyla
were identified in fecal samples. Among these, four phyla were considered
abundant within the community (≥1%), including Firmicutes, Bacteroidetes,
Proteobacteria, and Deferribacteres. CST treated mice had higher proportion
(P < 0.05, t-test) of Bacteroidetes and lower abundance (P < 0.01, t-test) of
Firmicutes in the feces compared to control animals.
to identify bacteria that were most characteristic of CST or
Control treatments. The PLS-DA analysis showed that the
genera Prevotella, Bacteroides, Ovatus, Parabacteroidesdistarosis,
TABLE 2 | Relative abundances of bacterial phyla in colonic mucosa
samples.
Phylum Groups Mean percentage of
sequence in total
bacterial population
SEM
Unclassified Control 0.122989 0.050167
CST 0.291527 0.19307
Acidobacteria Control 0.025735 0.010402
CST 0.033388 0.00685
Actinobacteria Control 0.095085 0.095085
CST 0.072405 0.031928
Armatimonadetes Control 0 0
CST 0.000879 0.000879
Bacteroidetes Control 8.06612 5.42359
CST 21.0435 6.556034
Chlamydiae Control 0 0
CST 0.00306 0.002007
Chlorobi Control 0 0
CST 0.002098 0.002098
Cyanobacteria Control 0.039247 0.022309
CST 0.175241 0.063441
Deferribacteres Control 6.923494 3.656936
CST 5.949701 2.168418
Fibrobacteres Control 0 0
CST 0.013779 0.012973
Firmicutes Control 10.13424 6.855156
CST 12.51866 5.161134
Lentisphaerae Control 0 0
CST 0.00457 0.00457
OD1 Control 0 0
CST 0.004988 0.00332
OP3 Control 0 0
CST 0.001604 0.001604
Planctomycetes Control 0.002067 0.002067
CST 0.004664 0.001662
Proteobacteria Control 72.02106 16.32041
CST 59.16764 11.01085
Spirochaetes Control 0 0
CST 0.082258 0.082258
TM7 Control 0 0
CST 0.007409 0.00482
Tenericutes Control 0.037096 0.019253
CST 0.371448 0.170574
Verrucomicrobia Control 2.532872 2.52412
CST 0.142801 0.117295
Parabacteroides, and Dorea were positively associated with the
CST treatment in the fecal samples (R2 = 0.94, Q2 = 0.57;
Figure 5). In addition, members of Alpharoteobacteria (Class),
Bacteroidales (Order), RF32 (Order), and YS2 (Order) also
showed a positive association with CST treatment in the fecal
samples (R2 = 0.94, Q2 = 0.57). A negative association with
the members of Adlercreutzia, Allobaculum, Bacteroidaceae
(Family), Clostridia (Class) and Ruminococcaceae (Family) were
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FIGURE 4 | Effect of CST treatment on the abundant phyla (≥1%)
present in the colonic mucosa-associated samples. After quality filtering
steps, 19 bacterial phyla were identified in colonic mucosa samples. Among
these, four phyla were considered abundant within the community (≥1%),
including Firmicutes, Bacteroidetes, Proteobacteria, and Deferribacteres. CST
treatment did not change the abundance of these phyla in colonic mucosa
samples.
evident in the fecal samples collected from CST-treated mice
(R2 = 0.94, Q2 = 0.57).
CST Treatment Influenced Colonic
Mucosa-Associated Bacterial Community
Composition at Lower Taxonomical Levels
in Mice
A hundred and seventy nine taxa were identified. Of these 84
taxa were considered abundant within the community, while 95
taxa were in low abundance. The relative abundance of various
genera/taxa with sequence percentages ≥0.01% of community
were analyzed using PLS-DA to identify bacteria that were most
characteristic of the CST or control treatments. The PLS-DA
analysis of the colonic mucosa samples showed that genera
Bifidobacterium and Stenotrophomonas had a positive association
with the CST treatment (R2 = 0.32, Q2 = 0.242; Figure 6).
Members of Bacteroidales (Order), Chitinophagaceae (Family),
Clostridiaceae (Family), Clostridiales (Order), Coriobacteriaceae
(Family), Pseudomonadaceae (Family), Rikenellaceae (Family),
Ruminococcaceae (Family), and YS2 (Order) also showed a
positive association with the CST treatment in the colonic
mucosa samples (R2 = 0.32, Q2 = 0.242; Figure 6).
CST Treatment Significantly Influenced the
Predicted Functional and Metabolic
Pathways of Fecal and Colonic
Mucosa-Associated Microbiota in Mice
To determine the functional KEGG pathways that could be
associated with the observed microbial changes, we compared
the functional pathways for the microbiota in the fecal and
colonic mucosa samples from the CST-treated group with those
of the control mice. Several metabolic pathways were determined.
Subsystems or pathways that had a significant positive or negative
correlation with CST treatment are shown in Figures 7, 8. In
the fecal samples from CST-treated mice, chlorocyclohexane and
chlorobenzene degradation were underrepresented (P = 0.015;
Figure 7). However, nitrogen metabolism was enriched in the
fecal samples fromCST-treatedmice (P= 0.033; Figure 7). In the
colonic mucosa samples from CST treated mice, nicotinate and
nicotinamide metabolism, cell division and ribosome biogenesis
were enriched compared to the controls (P < 0.05; Figure 8).
DISCUSSION
The mammalian intestine continuously encounters more
microorganisms than any other tissue, and survival of the
mammals largely depends on their unique adaption in the world
of microorganisms. Specific intestinal epithelial cells release
several antimicrobial peptides, which are critical for maintaining
a stable ecological environment that favors commensal and
targeting pathological microorganisms (Bals, 2000). Moreover,
these are also important for inhibiting ongoing inflammatory
responses. The CST, a highly conserved CgA peptide that
is present in intestinal EC cells, has been described as a
peptide with some immunomodulatory activities during acute
experimental colitis (Rabbi et al., 2014) and restricted in vitro
antibacterial activities (Aslam et al., 2012), but also antifungal
and antiviral activity (Boman et al., 1993; Dorschner et al., 2001).
Moreover, in a recent report, it has been observed that the CgA,
the precursor of CST strongly regulates human gut microbiome
(Zhernakova et al., 2016). However, there are no documented
studies demonstrating the effect of CST on gut microbiota using
in vivomodels. Here, we show that i.r. infusion of CSTmodulates
gut microbiota composition under physiological conditions.
Based on the α-diversity, we observed that bacterial richness
and diversity in both fecal and colonic mucosa samples did not
change after CST administration. However, β-diversity analysis
revealed that CST-treatedmice had a fecal microbial composition
that was different from the control group (P < 0.05, both
weighted and unweighted) suggesting that a short-term exposure
of this peptide in the gut might change the bacterial composition
profile. This is in accordance with studies demonstrating the
effect of other antibacterial peptides released by Paneth cells (i.e.,
defensin) on gut microbiota (Salzman et al., 2010).
Recent investigation shows that intestinal inflammatory
conditions, such as inflammatory bowel disease (IBD) or
inflammatory bowel syndrome (IBS), are associated with altered
intestinal homeostasis (Collins, 2014; Comito et al., 2014).
Although microbial dysbiosis has been suggested to be a cause of
intestinal pathophysiological conditions, this is still controversial,
however, gut dysbiosis can take part of the entire process. In
parallel, in human and animalmodels of IBS, it has been observed
that microbial diversity is significantly altered (Collins, 2014;
Comito et al., 2014). In the context of IBS, although an exact
causal microbe has not yet been identified, a reduction in the
microbial diversity has been documented and this temporal
gut microbiota instability can result in altered host physiology,
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FIGURE 5 | Partial least square discriminant analysis (PLS-DA) of bacterial communities comparing taxa that were associated with the Control or CST
treatments in the mice fecal samples. All taxa are colored based on the phyla to which they belong. Some sequences could only be affiliated to phylum (P), order
(O), family (F), or class (C) levels. Specific taxa were significantly associated with each treatment group, which may be an indicator of an alteration in the physiological
or metabolic processes that the taxa may influence.
resulting in heterogeneous symptoms such as those observed
in IBS patients (Collins, 2014; Comito et al., 2014). At the
phylum level, IBS patients have a relative higher abundance of
Firmicutes and lower abundance of Bacteroidetes (Collins, 2014).
In our study, we observed that CST treatment is significantly
associated with a relative reduction of Firmicutes in the feces
compared with saline-treated mice. Conversely, CST treatment
was associated with a significant relative increased abundance
of Bacteroidetes in the feces compared with saline-treated mice.
Beside IBS, also in colitic conditions, studies have demonstrated
a relative reduction in Bacteroidetes proportion (Nagalingam
et al., 2011). In a recent article, we also observed that acute
dextran sulfate sodium induced colitic mice have a lower relative
abundance of Bacteroidetes in their fecal samples compared to
control (Munyaka et al., 2016). In addition to colonic pathologies,
studies demonstrated that Firmicutes are significantly more
abundant relative to Bacteroidetes in obese mice compared to
lean mice (Kallus and Brandt, 2012); these results were also
observed in humans (Kallus and Brandt, 2012). In our study,
CST treatment was associated with a significant abundance of
Bacteroidetes relative to Firmicutes in fecal samples, which was
opposite to results from obese animals and humans. However,
these changes in Bacteroidetes and Firmicutes abundance were
not observed in the colonic mucosa samples suggesting that
prolonged administration of this peptide might be required to
observe a possible change in the colonic wall. Overall, this study
for the first time showed the in vivo effect of CST on murine gut
microbiota, which was not predictable from the in vitro effect
of CST on S. aureus and E. coli (Boman et al., 1993; Dorschner
et al., 2001). As gut microbiota is complex and composed of many
bacteria, which might not cultivable yet in vitro, their relative
abundance in vivo can be captured through high-throughput
sequencing.
The CST treatment also caused microbial alteration at
lower taxonomic levels. We observed that certain bacterial
taxa were positively associated with CST treatment in both
fecal and colonic mucosa samples. Among these taxa, genera
Bacteroides and Parabacteroides showed a positive association
with CST treatment in the fecal samples. Both of these belong
to the Bacteroidales order, which also showed a positive
association with CST treatment in the colonic mucosa samples.
Bacteroides and Parabacteroides spp. represent ∼25% of the
colonic microbiota and are commensal to the host when
present in the gut (Salyers, 1984). These anaerobic rods can
transform simple and complex sugars into volatile fatty acids,
which can be absorbed by the large intestine as a nutrient.
Bacteroides thetaiotaomicron has several starch-binding genes
and can produce significant amount of glycosylhydrolases,
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FIGURE 6 | Partial least square discriminant analysis (PLS-DA) of bacterial communities comparing taxa that were associated with the Control or CST
treatments in the mice colonic mucosa-associated samples. All taxa are colored based on the phyla to which they belong. Some sequences could only be
affiliated to phylum (P), order (O), family (F), or class (C) levels. Specific taxa were significantly associated with each treatment group, which may be an indicator of an
alteration in the physiological or metabolic processes that the taxa may influence.
FIGURE 7 | Subsystems and pathways enriched or decreased within the Catestatin (CST) or (Control) mice fecal samples. Corrected P-values were
calculated using the Storey FDR correction. Subsystems or pathways overrepresented in the CST or Control mice fecal samples have a positive or (negative)
difference between mean proportions and are indicated by purple or (orange) coloring, respectively.
which can be crucial to prevent obesity (Wexler, 2007). This
might explain why Bacteroidetes are more abundant in lean
mice compared to obese mice. Beside the enormous starch-
utilizing capacity, Bacteroides spp. are important for developing
gut immunity. For example, B. thetaiotaomicron can stimulate
Paneth cells to produce Paneth cell protein (Ang4), which
is lethal to certain pathogenic microorganisms (e.g., Listeria
monocytogenes; Hooper et al., 2003). In addition, Bacteroides
fragilis produces zwitter ionic polysaccharide (ZPS), which is
important for developing CD4 T cells. ZPS-activated CD4 T
cells produce interleukin-10 (IL-10), which is essential to prevent
abscess formation and other unchecked inflammatory responses
(Mazmanian and Kasper, 2006; Wexler, 2007; Round and
Mazmanian, 2010). Increased Bacteroides abundance in mice in
response to CST exposure might be beneficial to control obesity
and inflammatory conditions such as IBD or IBS. These results
might also explain the underlying mechanisms for improving gut
inflammation that we observed previously in colitic mice exposed
to CST (Rabbi et al., 2014).
Finally, our metagenomic prediction analysis helped
to understand the functionaly of microbiota in the given
environment (Chistoserdovai, 2010). Using this approach, we
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FIGURE 8 | Subsystems and pathways enriched or decreased within the Catestatin (CST) or (Control) mice colonic mucosa-associated samples.
Subsystems or pathways overrepresented in the CST or Control mice colon samples have a positive or (negative) difference between mean proportions and are
indicated by Purple or (orange) coloring, respectively.
observed that certain subsystems or pathways were enriched after
CST treatment suggesting that, although, we were not able to see
any effect for some markers studied after 6 days, treatment with
CST modified specific functional activities of the microbiota. In
this context, CST treatment induced functional alteration in the
murine intestinal microbiota, with some metabolic pathways
enriched in the mucosal microbiota of fecal and colonic mucosa
samples compared to the control mice. However, since this
was prediction and the specific changes observed might not
directly influence the host’s metabolic capacity, further studies
might shed more light on this topic. In conclusion, our findings
provide new insight into gut microbiota modulation by CST.
We observed an alteration in the microbial profile in response
to CST treatment, which was more prominent in the feces than
in colonic mucosa-associated bacterial community. This is an
observation based on a small number of samples, and the result
of this study needs to be further validated in a larger experiment
associated to a paired analysis of feces. Our results suggest new
avenues for the development of a potential new anti-microbial
peptide, which could be used as a therapeutic agent to treat
several gastrointestinal conditions such as IBD, IBS, however,
further studies are warrant.
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